



This is a peer-reviewed, post-print (final draft post-refereeing) version of the following in press document, "This article has been accepted for publication in Sexually Transmitted Infections, 2025 following peer review, and the Version of Record can be accessed online at <https://doi.org/10.1136/sextrans-2025-056584>." and is licensed under Creative Commons: Attribution-Noncommercial 4.0 license:

Palmer, Bret Sheldon, Walker, Mark, DeBurgh-Thomas, Andrew and Rees, Kerry J ORCID logoORCID: <https://orcid.org/0009-0005-0444-368X> (2025) Shingrix vaccination for recurrent genital herpes: a real-world clinic experience. Sexually Transmitted Infections. sextrans-2025. doi:10.1136/sextrans-2025-056584 (In Press)

"This article has been accepted for publication in Sexually Transmitted Infections, 2025 following peer review, and the Version of Record can be accessed online at <https://doi.org/10.1136/sextrans-2025-056584>."

Official URL: <https://doi.org/10.1136/sextrans-2025-056584>

DOI: <http://dx.doi.org/10.1136/sextrans-2025-056584>

EPrint URI: <https://eprints.glos.ac.uk/id/eprint/15213>

Disclaimer

The University of Gloucestershire has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material.

The University of Gloucestershire makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.

The University of Gloucestershire makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights.

The University of Gloucestershire accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement.

PLEASE SCROLL DOWN FOR TEXT.

Shingrix Vaccination For Recurrent Genital Herpes: A Real-World Clinic Experience

Bret Sheldon Palmer^a Mark Walker^b Andrew de Burgh-Thomas^c Kerry Rees^d

^a Sexual Health & HIV Medicine consultant doctor at Royal United Hospital, The Riverside Clinic, James Street West, Bath BA1 2BT.

^b Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, England, UK GL53 7AW

^c Sexual Health & HIV Medicine consultant doctor at The Fritchie Unit, Charlton Lane, Gloucestershire Royal Hospital, The Fritchie Unit, Charlton Lane. Gloucester, Gloucestershire, UK

^d University of Gloucestershire, School of Education and Science, Francis Close Hall, Swindon Road, Cheltenham, England, UK, GL50 4AZ

Correspondence:

Dear Editor

We report on the exploratory use of the recombinant herpes zoster vaccine (RZV, Shingrix) to manage recurrent genital HSV-2 infection in a male in his early 60s, with bi-monthly outbreaks causing substantial psychological and physical burden. Genital herpes was confirmed through HSV-2 detection in genital swabs, and previously managed with acyclovir, either episodically (400mg TDS for 5 days) or continuously (400mg BD). The medical history showed no immunodeficiency or significant comorbidities. VZV IgG status was not measured as this is not routinely assessed during an HSV review.

Vaccination with a VZV vaccine was considered based on evidence linking VZV IgG titres with risk of HSV outbreaks.¹ The recombinant zoster vaccine (RZV, Shingrix) was preferred for its higher demonstrated efficacy against herpes zoster compared with the attenuated virus-based vaccine.²

He received a RZV dose in July and again in November 2024 and was instructed to report to the clinic for any adverse reactions or outbreaks and to record the frequency of subsequent HSV-2 outbreaks over 6 months if unable to attend clinic.

During this period, the patient reported a decrease in herpes outbreaks, from 6 bi-monthly outbreaks the previous year to none in the following 6 months, with two episodes of 'tingling sensation' over the typical outbreak area but no sores, ulcers or skin lesions as self-reported by the patient. The patient was asked to provide a statement regarding his experience at the end of the 6 months. He wrote: "I immediately noticed a difference in

both the incidence and severity of herpes attacks. I have not had an outbreak since the summer, and this has been life-changing for me.”

This case suggests RZV's potential as an alternative to traditional HSV management. Additional investigation is needed to determine its applicability. The immunological correlation between VZV antibody levels and HSV recurrence rates,¹ warrants further study.

¹ Palmer BS, Tang A, Winchester S, Atkins M, Barton S, Kelleher P. Is the level of varicella-zoster virus IgG associated with symptomatic status of genital herpes simplex virus infection? A case-control study. *Int J STD AIDS*. 2024 Mar;35(4):314-318. doi: 10.1177/09564624231221172. Epub 2023 Dec 13. PMID: 38093464.

² Levin MJ, Weinberg A. Immune responses to zoster vaccines. *Hum Vaccin Immunother*. 2019;15(4):772-777. doi: 10.1080/21645515.2018.1560918. Epub 2019 Jan 24. PMID: 30676834; PMCID: PMC6605864.

Contribution Statement: BSP came up with the hypothesis, executed the work and wrote the manuscript. Bret S. Palmer / BSP are the guarantor

MW, ABT and KR, helped write and review the manuscript

Funding: This case report received no financial contribution.

Competing Interests: None declared.

Patient Consent for Publication: Obtained.

Ethics Approval: None required, patient went for Shingrix vaccine at the correct age for herpes zoster prevention, we monitored for changes in HSV reoccurrence.

Provenance and Peer Review: Not commissioned; internally peer-reviewed.